专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07192969B2 Ester derivatives 失效
标题翻译：酯衍生物
公开(公告)号：US07192969B2
公开(公告)日：2007-03-20
申请号：US10983613
申请日：2004-11-09
申请人： Yoshio Ogino , Hideki Kurihara , Kenji Matsuda , Tomoshige Numazawa , Norikazu Otake , Kazuhito Noguchi
发明人： Yoshio Ogino , Hideki Kurihara , Kenji Matsuda , Tomoshige Numazawa , Norikazu Otake , Kazuhito Noguchi
IPC分类号： A61K31/46 , C07D451/02
CPC分类号： C07D207/08 , C07C219/10 , C07C219/14 , C07D205/04 , C07D207/12 , C07D209/52 , C07D211/22 , C07D211/42 , C07D211/46 , C07D211/70 , C07D239/06 , C07D451/02 , C07D451/06 , C07D471/08 , C07D471/10 , C07D487/10
摘要： This invention relates to compounds which exhibit selective muscarinic M3 receptor antagonism, have little side effects, are suitable for inhalation therapy and are useful as treating agents of respiratory system diseases, of the general formula (I); [in which A signifies a group expressed by a formula (a0) or (b0); Ar signifies optionally substituted aryl or heteroaryl; B1 and B2 signify aliphatic hydrocarbon; R1 signifies fluorine-substituted cycloalkyl; R2, R3 and R4 signify lower alkyl, single bond or alkylene bonded to B1, or R2 and R3 are united to signify alkylene; R5 and R7 signify hydrogen, lower alkyl, or a single bond or alkylene bonded to B2; R6 signifies hydrogen, lower alkyl or a group expressed as —N(R8)R9; and X− signifies an anion].
摘要翻译：本发明涉及具有选择性毒蕈碱M 3受体拮抗作用，副作用小，适用于吸入治疗的化合物，并且可用作通式（I）的呼吸系统疾病的治疗剂; [其中A表示由式（a 0 ）或（b 0>）表示的组; Ar表示任选取代的芳基或杂芳基; B 1和B 2表示脂族烃; R 1表示氟取代的环烷基; R 2，R 3和R 4表示低级烷基，单键或与B 1连接的亚烷基，或 R 2和R 3结合起来表示亚烷基; R 5和R 7表示氢，低级烷基或键合到B 2的单键或亚烷基; R 6表示氢，低级烷基或以-N（R 8）R 9表示的基团; 和X - 表示阴离子]。

2. 发明申请

US20070129397A1 Ester derivatives 失效
标题翻译：酯衍生物
公开(公告)号：US20070129397A1
公开(公告)日：2007-06-07
申请号：US11648614
申请日：2007-01-03
申请人： Yoshio Ogino , Hideki Kurihara , Kenji Matsuda , Tomoshige Numazawa , Norikazu Otake , Kazuhito Noguchi
发明人： Yoshio Ogino , Hideki Kurihara , Kenji Matsuda , Tomoshige Numazawa , Norikazu Otake , Kazuhito Noguchi
IPC分类号： A61K31/46 , C07D451/00 , C07D211/34 , A61K31/445 , A61K31/40 , C07D207/04
CPC分类号： C07D207/08 , C07C219/10 , C07C219/14 , C07D205/04 , C07D207/12 , C07D209/52 , C07D211/22 , C07D211/42 , C07D211/46 , C07D211/70 , C07D239/06 , C07D451/02 , C07D451/06 , C07D471/08 , C07D471/10 , C07D487/10
摘要： This invention relates to compounds which exhibit selective muscarinic M3 receptor antagonism, have little side effects, are suitable for inhalation therapy and are useful as treating agents of respiratory system diseases, of the general formula (I); [in which A signifies a group expressed by a formula (a0) or (b0); Ar signifies optionally substituted aryl or heteroaryl; B1 and B2 signify aliphatic hydrocarbon; R1 signifies fluorine-substituted cycloalkyl; R2, R3 and R4 signify lower alkyl, single bond or alkylene bonded to B1, or R2 and R3 are united to signify alkylene; R5 and R7 signify hydrogen, lower alkyl, or a single bond or alkylene bonded to B2; R6 signifies hydrogen, lower alkyl or a group expressed as —N(R8)R9; and X−signifies an anion].
摘要翻译：本发明涉及具有选择性毒蕈碱M 3受体拮抗作用，副作用小，适用于吸入治疗的化合物，并且可用作通式（I）的呼吸系统疾病的治疗剂; [其中A表示由式（a 0 ）或（b 0>）表示的组; Ar表示任选取代的芳基或杂芳基; B 1和B 2表示脂族烃; R 1表示氟取代的环烷基; R 2，R 3和R 4表示低级烷基，单键或与B 1连接的亚烷基，或 R 2和R 3结合起来表示亚烷基; R 5和R 7表示氢，低级烷基或键合到B 2的单键或亚烷基; R 6表示氢，低级烷基或以-N（R 8）R 9表示的基团; 和X - 表示阴离子]。

3. 发明授权

US07504432B2 Ester derivatives 失效
标题翻译：酯衍生物
公开(公告)号：US07504432B2
公开(公告)日：2009-03-17
申请号：US11648614
申请日：2007-01-03
申请人： Yoshio Ogino , Hideki Kurihara , Kenji Matsuda , Tomoshige Numazawa , Norikazu Otake , Kazuhito Noguchi
发明人： Yoshio Ogino , Hideki Kurihara , Kenji Matsuda , Tomoshige Numazawa , Norikazu Otake , Kazuhito Noguchi
IPC分类号： A01N43/36 , C07D207/00
CPC分类号： C07D207/08 , C07C219/10 , C07C219/14 , C07D205/04 , C07D207/12 , C07D209/52 , C07D211/22 , C07D211/42 , C07D211/46 , C07D211/70 , C07D239/06 , C07D451/02 , C07D451/06 , C07D471/08 , C07D471/10 , C07D487/10
摘要： This invention relates to compounds which exhibit selective muscarinic M3 receptor antagonism, have little side effects, are suitable for inhalation therapy and are useful as treating agents of respiratory system diseases, of the general formula (I); [in which A signifies a group expressed by a formula (a0) or (b0); Ar signifies optionally substituted aryl or heteroaryl; B1 and B2 signify aliphatic hydrocarbon; R1 signifies fluorine-substituted cycloalkyl; R2, R3 and R4 signify lower alkyl, single bond or alkylene bonded to B1, or R2 and R3 are united to signify alkylene; R5 and R7 signify hydrogen, lower alkyl, or a single bond or alkylene bonded to B2; R6 signifies hydrogen, lower alkyl or a group expressed as —N(R8)R9; and X− signifies an anion].
摘要翻译：本发明涉及具有选择性毒蕈碱M3受体拮抗作用，副作用小，适用于吸入治疗的化合物，并且可用作通式（I）的呼吸系统疾病的治疗剂; [其中A表示由式（a0）或（b0）表示的组; Ar表示任选取代的芳基或杂芳基; B1和B2表示脂族烃; R1表示氟取代的环烷基; R2，R3和R4表示低级烷基，单键或与B1键合的亚烷基，或者R2和R3相连，表示亚烷基; R5和R7表示氢，低级烷基或键合到B2的单键或亚烷基; R6表示氢，低级烷基或表示为-N（R8）R9的基团; 和X-表示阴离子]。

4. 发明申请

US20050065211A1 Ester derivatives 失效
标题翻译：酯衍生物
公开(公告)号：US20050065211A1
公开(公告)日：2005-03-24
申请号：US10983613
申请日：2004-11-09
申请人： Yoshio Ogino , Hideki Kurihara , Kenji Matsuda , Tomoshige Numazawa , Norikazu Otake , Kazuhito Noguchi
发明人： Yoshio Ogino , Hideki Kurihara , Kenji Matsuda , Tomoshige Numazawa , Norikazu Otake , Kazuhito Noguchi
IPC分类号： A61P11/00 , A61P11/06 , A61P27/16 , A61P43/00 , C07C219/10 , C07C219/14 , C07D205/04 , C07D207/08 , C07D207/12 , C07D209/52 , C07D211/22 , C07D211/42 , C07D211/46 , C07D211/70 , C07D239/06 , C07D451/02 , C07D451/06 , C07D471/08 , C07D471/10 , C07D487/10 , C07D498/10 , A61K31/445 , A61K31/24 , C07C229/52
CPC分类号： C07D207/08 , C07C219/10 , C07C219/14 , C07D205/04 , C07D207/12 , C07D209/52 , C07D211/22 , C07D211/42 , C07D211/46 , C07D211/70 , C07D239/06 , C07D451/02 , C07D451/06 , C07D471/08 , C07D471/10 , C07D487/10
摘要： This invention relates to compounds which exhibit selective muscarinic M3 receptor antagonism, have little side effects, are suitable for inhalation therapy and are useful as treating agents of respiratory system diseases, of the general formula (I); [in which A signifies a group expressed by a formula (a0) or (b0); Ar signifies optionally substituted aryl or heteroaryl; B1 and B2 signify aliphatic hydrocarbon; R1 signifies fluorine-substituted cycloalkyl; R2, R3 and R4 signify lower alkyl, single bond or alkylene bonded to B1, or R2 and R3 are united to signify alkylene; R5 and R7 signify hydrogen, lower alkyl, or a single bond or alkylene bonded to B2; R6 signifies hydrogen, lower alkyl or a group expressed as —N(R8)R9; and X− signifies an anion].
摘要翻译：本发明涉及具有选择性毒蕈碱M3受体拮抗作用，副作用小，适用于吸入治疗的化合物，并且可用作通式（I）的呼吸系统疾病的治疗剂; [其中A表示由式（a0）或（b0）表示的组; Ar表示任选取代的芳基或杂芳基; B 1和B 2表示脂族烃; R 1表示氟取代的环烷基; R 2，R 3和R 4表示低级烷基，单键或与B 1键合的亚烷基，或R 2和R 3一起表示亚烷基; R 5和R 7表示氢，低级烷基或与B 2键合的单键或亚烷基; R 6表示氢，低级烷基或以-N（R 8）R 9表示的基团; 而X - 表示阴离子]。

5. 发明授权

US06846835B2 Ester derivatives 失效
标题翻译：酯衍生物
公开(公告)号：US06846835B2
公开(公告)日：2005-01-25
申请号：US10332617
申请日：2001-07-10
申请人： Yoshio Ogino , Hideki Kurihara , Kenji Matsuda , Tomoshige Numazawa , Norikazu Otake , Kazuhito Noguchi
发明人： Yoshio Ogino , Hideki Kurihara , Kenji Matsuda , Tomoshige Numazawa , Norikazu Otake , Kazuhito Noguchi
IPC分类号： A61P11/00 , A61P11/06 , A61P27/16 , A61P43/00 , C07C219/10 , C07C219/14 , C07D205/04 , C07D207/08 , C07D207/12 , C07D209/52 , C07D211/22 , C07D211/42 , C07D211/46 , C07D211/70 , C07D239/06 , C07D451/02 , C07D451/06 , C07D471/08 , C07D471/10 , C07D487/10 , C07D498/10 , A61K31/445 , A61K31/4465 , C07D211/04 , C07D221/02
CPC分类号： C07D207/08 , C07C219/10 , C07C219/14 , C07D205/04 , C07D207/12 , C07D209/52 , C07D211/22 , C07D211/42 , C07D211/46 , C07D211/70 , C07D239/06 , C07D451/02 , C07D451/06 , C07D471/08 , C07D471/10 , C07D487/10
摘要： This invention relates to compounds which exhibit selective muscarinic M3 receptor antagonism, have little side effects, are suitable for inhalation therapy and are useful as treating agents of respiratory system diseases, of the general formula (I); [in which A signifies a group expressed by a formula (a0) or (b0); Ar signifies optionally substituted aryl or heteroaryl; B1 and B2 signify aliphatic hydrocarbon; R1 signifies fluorine-substituted cycloalkyl; R2, R3 and R4 signify lower alkyl, single bond or alkylene bonded to B1, or R2 and R3 are united to signify alkylene; R5 and R7 signify hydrogen, lower alkyl, or a single bond or alkylene bonded to B2; R6 signifies hydrogen, lower alkyl or a group expressed as —N(R8)R9; and X− signifies an anion].
摘要翻译：本发明涉及具有选择性毒蕈碱性M3受体拮抗作用，副作用小，适用于吸入治疗的化合物，并且可用作通式（I）的呼吸系统疾病的治疗剂; [其中A表示一组表达通式（a0）或（b0）; Ar表示任选取代的芳基或杂芳基; B 1和B 2表示脂族烃; R 1表示氟取代的环烷基; R 2，R 3和R 4表示低级烷基，单键或与B 1键合的亚烷基，或R 2和R 3一起表示亚烷基; R 5和R 7表示氢，低级烷基或与B 2键合的单键或亚烷基; R 6表示氢，低级烷基或以-N（R 8）R 9表示的基团; 而X - 表示阴离子]。

6. 发明授权

US07164024B2 Benzimidazolone derivatives 失效
标题翻译：苯并咪唑酮衍生物
公开(公告)号：US07164024B2
公开(公告)日：2007-01-16
申请号：US10475447
申请日：2002-04-19
申请人： Takeru Yamakawa , Yoshio Ogino , Yufu Sagara , Kenji Matsuda , Akira Naya , Toshifumi Kimura , Norikazu Otake
发明人： Takeru Yamakawa , Yoshio Ogino , Yufu Sagara , Kenji Matsuda , Akira Naya , Toshifumi Kimura , Norikazu Otake
IPC分类号： A61K31/44
CPC分类号： C07D401/14 , C07D409/14
摘要： This invention relates to benzimidazolone derivatives, represented by compounds of a general formula [I] [in which R1 and R2 stand for, e.g., hydrogen atoms; R3a, R3b, R4, R5 stand for, e.g., hydrogen atoms and alkyl groups; R6 stands for e.g., aryl or heteroaryl groups; A ring stands for 5- to 8-membered aliphatic heterocyclic ring containing one nitrogen atom; and Z stands for carbonyl group or sulfonyl group]. The benzimidazolone derivatives of the invention exhibit antagonism to muscarinic acetylcholine receptors, and are useful as treating agent and/or prophylactic of Parkinson's disease, drug-induced parkinsonism, dystonia, akinesia, pancreatitis, bilestone/cholecystitis, biliary dyskinesia, achalasia, pain, itch, cholinergic urticaria, irritable bowel syndrome, vomiting, nausea, dizziness, Meniere's disease, motion sickness and urinary disturbance.
摘要翻译：本发明涉及由通式[I] [其中R 1，R 2和R 2]的化合物代表的例如氢原子的苯并咪唑酮衍生物; R 3a，R 3b，R 4，R 5表示例如氢原子和烷基; R 6表示例如芳基或杂芳基; 环代表含有一个氮原子的5-至8-元脂族杂环; Z代表羰基或磺酰基]。本发明的苯并咪唑酮衍生物对毒蕈碱性乙酰胆碱受体表现出拮抗作用，可用作帕金森病，药物诱发的帕金森综合征，肌张力障碍，运动不良，胰腺炎，胆石，胆囊炎，胆汁运动障碍，贲门失弛缓症，疼痛，瘙痒的治疗剂和/或预防，胆碱能性荨麻疹，肠易激综合征，呕吐，恶心，眩晕，梅尼埃病，运动病和尿紊乱。

7. 发明申请

US20060205750A1 Novel benzimidazole derivatives 失效
公开(公告)号：US20060205750A1
公开(公告)日：2006-09-14
申请号：US11431274
申请日：2006-05-10
申请人： Norikazu Otake , Minoru Moriya , Yoshio Ogino , Kenji Matsuda , Yoshikazu Nagae , Akio Kanatani , Takehiro Fukami
发明人： Norikazu Otake , Minoru Moriya , Yoshio Ogino , Kenji Matsuda , Yoshikazu Nagae , Akio Kanatani , Takehiro Fukami
IPC分类号： A61K31/4747 , A61K31/4184 , C07D487/10
CPC分类号： C07D473/30 , C07D405/04 , C07D471/04 , C07D471/10 , C07D473/00 , C07D491/04
摘要： The present invention relates to a compound of the formula (I): (wherein A, B, C and D are independently nitrogen or optionally substituted methine; E is nitrogen, methine or hydroxy substituted methine; n is 0 or 1; T, U, V and W are independently nitrogen or optionally substituted methine; X is —N(SO2R4)—, —N(COR5)— or —CO—; Y is —C(R6)(R7)—, —O— or —N(R8)—, provided that the compound (I) when E is nitrogen, n is 0, X is —CO—, and Y is —O— is excluded) and the like, which are useful as an agent for the treatment of various diseases related to NPY, for example cardiovascular disorders such as angina, acute or congestive heart failure, myocardial infarction, hypertension, nephropathy, electrolyte abnormality, vasospasm, arteriosclerosis, etc., central nervous system disorders such as bulimia, depression, anxiety, seizure, epilepsy, dementia, pain, alcoholism, drug withdrawal, circadian rhythm disorders, schizophrenia, memory impairment, sleep disorders, cognitive impairment, etc., metabolic diseases such as obesity, diabetes, hormone abnormality, hypercholesterolemia, hyperlipidemia, gout, fatty liver, etc., genital or reproductive disorders such as infertility, preterm labor, sexual dysfunction, etc., gastro-intestinal disorders, respiratory disorder, inflammatory diseases or glaucoma, and the like, also for example, atherosclerosis, hypogonadism, hyperandrogenism, polycystic ovary syndrome (Pickwickian syndrome), hirsutism, gastro-intestinal motility disorder, obesity-related gastro-esophageal reflux, obesity hypoventilation, sleep apnea, inflammation, systemic inflammation of the vasculature, osteoarthritis, insulin resistance, bronchoconstriction, alcohol preference, metabolic syndrome, Alzheimer's disease, cardiac hypertrophy, left ventricular hypertrophy, hypertriglyceridemia, low HDL cholesterol, cardiovascular disorders such as coronary heart disease (CHD), cerebrovascular disease, stroke, peripheral vascular disease, sudden death, gallbladder diseases, cancer (breast, endometrial, colon), breathlessness, hyperuricemia, impaired fertility, low back pain, or increased anesthetic risk, and the like.

8. 发明授权

US07803807B2 Benzimidazole derivatives 失效
标题翻译：苯并咪唑衍生物
公开(公告)号：US07803807B2
公开(公告)日：2010-09-28
申请号：US12605503
申请日：2009-10-26
申请人： Norikazu Otake , Minoru Moriya , Yoshio Ogino , Kenji Matsuda , Yoshikazu Nagae , Akio Kanatani , Takehiro Fukami
发明人： Norikazu Otake , Minoru Moriya , Yoshio Ogino , Kenji Matsuda , Yoshikazu Nagae , Akio Kanatani , Takehiro Fukami
IPC分类号： A61K31/438 , C07D401/14 , A61P3/10
CPC分类号： C07D473/30 , C07D405/04 , C07D471/04 , C07D471/10 , C07D473/00 , C07D491/04
摘要： The present invention relates to compounds of Formula (I) wherein A, B and C are independently methine, said methine being optionally substituted; D is nitrogen; T, U, V and W are independently methine or nitrogen, said methine being optionally substituted and least two of T, U, V and W are said methine groups; X is —N(SO2R4)—, N(COR5)— or —CO—; Y is C(R6)(R7)—, —O— or —N(R8) and a pharmaceutically acceptable salt, ester or N-oxide derivative thereof.
摘要翻译：本发明涉及式（I）的化合物，其中A，B和C独立地为次甲基，所述次甲基任选被取代; D是氮; T，U，V和W独立地是次甲基或氮，所述次甲基任选被取代，T，U，V和W中的至少两个是所述次甲基; X是-N（SO 2 R 4） - ，N（COR 5） - 或-CO-; Y是C（R6）（R7） - ， - O-或-N（R8）及其药学上可接受的盐，酯或N-氧化物衍生物。

9. 发明授权

US07687514B2 Benzimidazole derivatives 失效
标题翻译：苯并咪唑衍生物
公开(公告)号：US07687514B2
公开(公告)日：2010-03-30
申请号：US11431274
申请日：2006-05-10
申请人： Norikazu Otake , Minoru Moriya , Yoshio Ogino , Kenji Matsuda , Yoshikazu Nagae , Akio Kanatani , Takehiro Fukami
发明人： Norikazu Otake , Minoru Moriya , Yoshio Ogino , Kenji Matsuda , Yoshikazu Nagae , Akio Kanatani , Takehiro Fukami
IPC分类号： A61K31/4747 , C07D221/20
CPC分类号： C07D473/30 , C07D405/04 , C07D471/04 , C07D471/10 , C07D473/00 , C07D491/04
摘要： The present invention relates to a compound of the formula (I): (wherein A, B, C and D are independently nitrogen or optionally substituted methine; E is nitrogen, methine or hydroxy substituted methine; n is 0 or 1; T, U, V and W are independently nitrogen or optionally substituted methine; X is —N(SO2R4)—, —N(COR5)— or —CO—; Y is —C(R6)(R7)—, —O— or —N(R8)—, provided that the compound (I) when E is nitrogen, n is 0, X is —CO—, and Y is —O— is excluded) and the like, which are useful as an agent for the treatment of various diseases related to NPY.
摘要翻译：本发明涉及式（I）化合物：其中A，B，C和D独立地为氮或任选取代的次甲基; E为氮，次甲基或羟基取代的次甲基; n为0或1; T，U ，V和W独立地为氮或任选取代的次甲基; X为-N（SO2R4） - ， - N（COR5） - 或-CO-; Y为-C（R6）（R7） - ， - O-或-N （R8） - ，条件是当E为氮时的化合物（I），n为0，X为-CO-，Y为-O-时除外）等，其可用作治疗与NPY相关的各种疾病。

10. 发明授权

US07105526B2 Benzimidazole derivatives 失效
标题翻译：苯并咪唑衍生物
公开(公告)号：US07105526B2
公开(公告)日：2006-09-12
申请号：US10463390
申请日：2003-06-18
申请人： Norikazu Otake , Minoru Moriya , Yoshio Ogino , Kenji Matsuda , Yoshikazu Nagae , Akio Kanatani , Takehiro Fukami
发明人： Norikazu Otake , Minoru Moriya , Yoshio Ogino , Kenji Matsuda , Yoshikazu Nagae , Akio Kanatani , Takehiro Fukami
IPC分类号： A61K31/52 , C07D239/70
CPC分类号： C07D473/30 , C07D405/04 , C07D471/04 , C07D471/10 , C07D473/00 , C07D491/04
摘要： The present invention relates to novel benzimidazole derivatives which are useful as neuropeptide Y receptor antagonists.
摘要翻译：本发明涉及可用作神经肽Y受体拮抗剂的新型苯并咪唑衍生物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式